Features of TSD

01

Focus on three therapeutic areas(GI EndoTherapy, Urology, and Respiratory)

In TSD, we contribute to minimally invasive treatment across multiple clinicalspecialties. In particular, we continue to strengthen the product portfolio in thecategories of GI EndoTherapy, Urology, and Respiratory.

02

Globally managed from the U.S.

Strengthen access to key medical clusters and customers in the U.S., the world's
largest therapeutic device market.

TSD

03

Enhance capabilities and increase activity in businessdevelopment in an effort to expand the product portfolio
through external partnerships, licensing and M&A

Conducted multiple M&A activities, mainly in the GI EndoTherapy, Urology, andRespiratory.

Market scale and growth forecast of each area

Therapeutic Solutions Division
In its Therapeutic Solutions Business, Olympus uses innovative capabilities inmedical technology, therapeutic intervention, and precision manufacturing tohelp healthcare professionals deliver diagnostic, therapeutic, and minimallyinvasive procedures to improve clinical outcomes, reduce overall costs, andenhance the quality of life for patients. Starting with its early contributions tothe development of the polypectomy snare, Olympus Therapeutic Solutions

GI EndoTherapy

Urology

Respiratory¥350 – 450¥400 – 500¥ 100 – 150

Market CAGR 5 – 7%Market CAGR 5 – 7%Market CAGR 6 – 7%billionbillionbillionportfolio has grown to include an array of surgical energy devices and a wide
range of instruments to help prevent, detect, and treat disease.
Note: Served market scale and growth forecast information for this page come from the Company’s research and pertains to data for the U.S., EU5 (Germany, UK, Italy, France, Spain),Japan and China, Market scale is as of March 31, 2023, Growth forecasts are projected for fiscal year 2023 to fiscal year 2026. Sub-segment sales ratios within TSD are figures offiscal year 2023.

1819

01

Focus on three therapeutic areas(GI EndoTherapy, Urology, and Respiratory)

Urology

Focus areas in the TSD

Category

In TSD, we focus on areas where we are highly competitive. In the areas of GI EndoTherapy, Urology, and Respiratory,
we are in a strong position to grow through investments in our product portfolio, educating the market on new,advanced, therapeutic techniques, and leveraging our global sales channels.

2GI EndoTherapy

Urology

Respiratory

Market Share

Market Share

Market ShareNo. 2Approx. 30% of
TSD revenue

No. 2Approx. 15% of
TSD revenue

1Olympus
Right to Win
CAGR FY2024-FY2026:
High single-digit %GI EndoTherapy
Category

2 Urinary stone

Minimally invasive treatment
device for BPH

Thulium fiber laser system

1 Hemostasis

Hemostasis clip

4 Stenosis release

2 ESD*2 & EMR*3

3 ERCP*1

Launch of single-use ureteroscope will expand clinician optionsP ortfolio of Laser and Ultrasonic lithotripsy systems enables market share capturePLASMA+ system, one of the growth drivers, continues solid growth xpanded reimbursement for differentiated MIS BPH device which provides
Ebetter clinical outcomes and elevates the standard of care*4

Respiratory

Resection anddissection device

5 Sampling

ERCP device

ThoracicTracheobronchial
lymph nodestree
Esophagus

1 EBUS-TBNA(Endobronchial ultrasoundtransbronchial needle
aspiration)

EBUS-TBNA systemStentBiopsy forceps

Colonoscope distalattachment

Intrabronchial valve system

Peripheral pulmonarylesionOlympus
Right to Win
CAGR FY2024-FY2026:
Mid single-digit % ifferentiated solutions such as EVIS X1 bronchoscopes and EU-ME3
Dendoscopic ultrasound processor expected to drive robust future growth ommitted to delivering meaningful innovation to optimize patient outcomesCin bronchoscopy and lung cancer staging & diagnosis procedures

Double-digit growth in our ESD/EMR, ENDOCUFF VISION, EndoClot portfolios
Acquisition of broad metal stent portfolio will significantly accelerate ourglobal position and options in biliary tract, esophagus, colon, andduodenum treatments

Please refer to pages 24-30 for main diseases, procedures, and products in this area.

202 Diagnostic andtherapeutic
bronchoscopy

6 Device forendoscopy

Lung

CAGR FY2024-FY2026:
High single-digit %Resectoscope

Please refer to pages 31-32 for main diseases, procedures, and products in this area.

Category

Olympus
Right to Win

3 Bladder tumor(bladder cancer)

2 3

No.1

Approx. 35% ofTSD revenue

21 Benign prostate
hyperplasia(BPH)

Please refer to pages 32-33 for main diseases, procedures, and products in this area.

*1 Endoscopic Retrograde Cholangio Pancreatography*2 Endoscopic Submucosal Dissection*3 Endoscopic Mucosal Resection*4	iTind procedure does not require a permanent implant and preserves sexual function and continence, while reducing the need for a post procedure catheter. Procedure can be done in the MD
office setting.

21

02

Globally managed from the U.S.

Olympus' global headquarters for the TSD is located in the U.S., which is
the world's largest market for therapeutic devices and the highest-sellingmarket in our business.
We also make global decisions in the U.S. because we have accessto a large number of hospitals, research institutions, competitors, andcustomers.
U.S.-based global
headquarters for the TSD

03

Enhance capabilities and increase acitivity inbusiness development in an effort to expand theproduct portfolio through external partnerships,licensing, and M&A

The establishment of a global headquarters in the U.S. has enabled us to efficiently and quickly expand andcomplement our product portfolio through collaboration with external partners, licensing, and M&A. In August2020, we acquired Arc Medical Design Ltd., a UK medical device manufacturer, and in May 2021, Medi-TateLtd., an Israeli medical device company. We are expanding our portfolio respectively. In order to contribute tominimally invasive treatments, we will continue to accelerate our growth not only through in-housedevelopment but also by considering external partnership and distribution agreement.

M&A
In August 2020, Olympus acquired Arc Medical Design Ltd., a UK medical device manufacturer, toexpand its portfolio of GI EndoTherapy.

Arc Medical Design

Representative product: ENDOCUFF VISION
A device that attaches to the distal end of a colonoscope, designed to help maintain visibility duringcolonoscopy and endoscopic polypectomy by allowing the flexible arm to scrape the folds of thecolon and fix the mucosa.

In May 2021, Olympus acquired Medi-Tate Ltd., an Israeli medical device company, to expand its
urology portfolio.

Medi-Tate

22

Representative product: iTindA minimally invasive treatment device for the treatment of BPH. It allows for day treatment in medicaloffices and clinics, no permanent implants for the patient, and a wide range of re-treatment options.